Comprehensive guides with safety triggers, contrarian views, research gaps, and practical protocol references.
A synthetic heptapeptide that acts as a molecular GPS for your body's repair crew — directing cell migration, building new blood vessels into injured tissue, and potentially re-activating embryonic healing pathways.
TB-500 is the synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in actin regulation, cell migration, and tissue repair. Its unique mechanism targets the body's internal repair logistics rather than just providing raw materials.
A 15-amino-acid gastric pentadecapeptide that coordinates multi-system repair through angiogenesis, collagen synthesis, and gut-brain axis stabilization.
BPC-157 is a synthetic peptide derived from human gastric juice, notable for its extreme biochemical stability and capacity to coordinate tissue repair across musculoskeletal, vascular, and neurological systems.
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "willpower" myth of obesity. Yet, a frustrating biological reality has emerged: the "weight loss wall." Enter Retatrutide — the world's first triple agonist designed to re-engineer the metabolic equation entirely.
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "will
The best immune peptides aren't the ones that turn the system up. They're the ones that teach it when to hold still.
Immune regulation is about homeostasis, not amplification. Thymosin Alpha-1 acts as a thermostat — pushing Th1 when the system is under-responsive, pushing T-regs when it's over-firing. Bioregulators work upstream at the level of gene expression. Thymosin Beta-4 regenerates across organ systems. Selank bridges the brain-immune axis. Understanding when to use each — and when not to — is the difference between peptide therapy and peptide tourism.
Cardiac peptide therapy isn't science fiction — Tβ4 has completed Phase 2 in acute MI (NCT05984134), and SS-31 sits in advanced-phase trials for mitochondrial heart disease.
A plain-English look at the peptides being investigated for cardiovascular repair — Thymosin β4 for post-infarct tissue regeneration, elamipretide for mitochondrial membrane stability, and the adjacent vascular-bioregulator layer.
Inflammation isn't just something to suppress — peptides like ARA-290 and KPV suggest you can reprogram the response entirely.
A plain-English look at the peptides being investigated for inflammation and tissue repair — what the evidence shows, what's still missing, and where the safety line sits.
Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.
Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.
Peptide-based gut healing splits across four mechanistically distinct compounds acting on different layers of the gastrointestinal barrier. The animal dossier is extensive; the human evidence is sparse; the regulatory posture is sceptical. An honest map of what is known, what is guessed, and where the practical safety decisions actually are.
BPC-157 drives angiogenesis and tissue repair. Larazotide antagonises zonulin to re-seal tight junctions. KPV suppresses NF-κB-driven inflammation. LL-37 reinforces the antimicrobial and mucus defence. The mechanism map is coherent. The human trial record — Larazotide's discontinued Phase III, BPC-157's three small pilots, the FDA's Category 2 classification — is sobering. Grey-market sourcing, not the peptides themselves, is the dominant source of documented harm.
GLP-1 agonists became a cultural phenomenon because they deliver dramatic short-term weight loss. The honest framing is chronic-disease pharmacology — effective while taken, compensation when withdrawn, best used alongside the nutritional foundation the drug amplifies.
Peptide-based appetite suppression splits across four classes — incretin agonists (semaglutide, tirzepatide, retatrutide), amylin analogs (cagrilintide), hypothalamic peptides (BRP), and growth-hormone fragments (AOD-9604). The multi-pathway arms race is producing larger weight losses, the weight-regain-on-discontinuation pattern is producing harder questions, and the nutritional foundation is producing the difference between therapeutic weight loss and iatrogenic frailty.
GLP-1 agonism is the headline. The full picture is three distinct peptide classes acting on glucose metabolism through three different mechanisms — and the honest protocol leads with the one that has actually passed regulatory scrutiny.
The peptide approach to blood sugar regulation splits into three distinct classes — incretin receptor agonists (GLP-1, dual GLP-1/GIP), mitochondrial-derived peptides (MOTS-c), and Khavinson bioregulators (Pankragen). Each sits on a different shelf of the evidence stack, each has a different risk profile, and the most common protocol error is treating them as interchangeable.
Sleep is not a pause — it is the most active regenerative state your biology runs. The peptides here tune its architecture without sedating the system.
Most sleep aids work by suppressing the central nervous system. A small class of peptides — DSIP, Epitalon, and the CJC-1295 / Ipamorelin stack — take the opposite approach: they restore the body's own sleep rhythms, hormonal pulses, and cellular repair cycles. This is sleep as biological fine-tuning, not sedation.
An evidence-based map of synthetic glyprolines — Selank, Semax, NPY and Pinealon — peptides engineered to modulate the HPA axis and amygdala reactivity without the sedation, dependence or cognitive blunting of benzodiazepines.
A rigorous look at the neuropeptide approach to modern stress: the Pro-Gly-Pro stability trick, the GABAergic-but-not-sedative mechanism of Selank, Semax's ACTH-derived neuroprotection, the Russian clinical evidence base, and the FDA Category 2 constraint that defines legal reality in the US.